Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1Phase 1 1

Status

Completed 3Terminated 1

Sponsor Class

OTHER 3NETWORK 1

Study Type

Interventional 4

Sponsor

Cancer Type

Dermatologic 4Sarcoma 1CNS 1

Conditions

Neuroblastoma 4Melanoma 4Osteosarcoma 2Sarcoma 1

Interventions

pembrolizumab 300Nivolumab 273Ipilimumab 250aldesleukin 137Cyclophosphamide 136Interleukin-2 105trametinib 82dabrafenib 76Temozolomide 75Dacarbazine 74Vemurafenib 71fludarabine 68fludarabine phosphate 62Biopsy 49binimetinib 47sargramostim 44Radiosurgery 44Bevacizumab 43Paclitaxel 42encorafenib 40incomplete Freund's adjuvant 39atezolizumab 38Radiotherapy 37Specimen Handling 36Cisplatin 36CTLA-4 Antigen 36Magnetic Resonance Spectroscopy 35Carboplatin 35cobimetinib 34Introns 33

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Melanoma × lorukafusp alfa × Clear all
NCT03958383 2026-06-03

IT-hu14.18-IL2 With Radiation, Nivolumab and Ipilimumab for Melanoma

University of Wisconsin, Madison

Phase 1/2 Terminated
8 enrolled 12 charts
Dermatologic

Melanoma

NCT00590824 2019-11-21

Pilot hu14.18-IL2 in Resectable Recurrent Stage III or Stage IV Melanoma

University of Wisconsin, Madison

Phase 2 Completed
23 enrolled 22 charts
Dermatologic

Melanoma

NCT00109863 2019-11-19

Hu14.18-Interleukin-2 Fusion Protein in Treating Patients With Advanced Melanoma

University of Wisconsin, Madison

Phase 2 Completed
14 enrolled
Dermatologic

Melanoma

NCT00003750 2014-08-08

Biological Therapy in Treating Children With Refractory or Recurrent Neuroblastoma or Other Tumors

Children's Oncology Group

Phase 1 Completed
28 enrolled
CNSDermatologicSarcoma

Melanoma, Neuroblastoma, Sarcoma, Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡